Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicago Inc MDCGF



GREY:MDCGF - Post by User

Comment by alexl1on Oct 01, 2010 11:19am
344 Views
Post# 17517493

RE: Medicago holds official groundbreaking ceremon

RE: Medicago holds official groundbreaking ceremonMr Wanner new Medicago Vice President US operations was CEO of Abeome Corp.. I wasn't aware that Medicago already had a collaboration with Abeome.



Abeome Announces a Collaboration with Medicago to Develop Neutralizing Monoclonal

Antibodies to the H5N1 and H1N1 Influenza VLPs

Athens, GA, March 12, 2010, Abeome Corporation, a Georgia-based biotech company, today

announced a collaboration with Medicago Inc. (TSX-V: MDG), a biotechnology company

focused on developing highly effective and affordable vaccines based on proprietary

manufacturing technologies and Virus-Like Particles (VLPs), to develop neutralizing

monoclonal antibodies to Medicago’s H5N1 and H1N1 VLPs using its patented DiSH (Direct

Selection of Hybridoma) technology.

"Availability of a neutralizing antibody treatment for patients suffering from severe influenza

disease would greatly improve upon the current antiviral treatments which typically provide

benefit only when administered shortly after the onset of infection,” states Mike Wanner,

President and CEO of Abeome. “Medicago’s influenza VLP vaccines which contain the most

abundant surface protein of the influenza virus will aid us in developing a significant library of

antibodies to screen for high affinity and cross-reactivity with a number of influenza-types.”

“Collaborating with Abeome, a biotech company focused on the commercialization of its

patented mAb-discovery platform, will potentially enhance access to unique, highly-specific

mAbs to the influenza viruses.” said Andy Sheldon, President and CEO of Medicago.

<< Previous
Bullboard Posts
Next >>